Production (Stage)
Entrada Therapeutics, Inc.
TRDA
$7.59
-$0.26-3.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 5.52% | 1,081.69% | 352.42% | 226.80% | 129.50% |
| Total Depreciation and Amortization | 17.04% | 32.81% | 33.68% | 47.60% | 58.06% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 52.84% | 7.71% | -8.73% | -20.81% | -38.75% |
| Change in Net Operating Assets | 23.93% | -187.19% | -162.79% | -170.31% | -161.93% |
| Cash from Operations | 38.79% | -129.73% | -111.99% | -112.50% | -168.23% |
| Capital Expenditure | 27.59% | 43.75% | 34.55% | 8.50% | -20.78% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 31.81% | 81.44% | 56.02% | 115.23% | -1,761.67% |
| Cash from Investing | 31.53% | 79.91% | 55.20% | 111.77% | -849.66% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 5,940.95% | 389.49% | 393.90% | 403.17% | -91.45% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 5,940.30% | 389.44% | 393.85% | 403.17% | -91.45% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 99.62% | 49.74% | 1,931.14% | 1,048.49% | -211.33% |